NCT01147224已完成不适用
Alvesco for the Therapy of Persistent Asthma With or Without Allergic Component
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 400
- 试验地点
- 1
- 主要终点
- Treatment success with Alvesco
研究概览
简要总结
The aim of the study is to evaluate the efficacy of Alvesco in patients with persistent asthma including or excluding allergic components over 3 months, especially in the spring season. Alvesco will be inhaled by a metered-dose inhaler. The study will provide further data on safety and tolerability of Alvesco .
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Asthma with or without allergic components
排除标准
- •Hypersensitive to compounds of Alvesco
- •Other criteria as defined in the Summary of Product Characteristics, Chapter 4.3
研究组 & 干预措施
ATEM
A prospective one-arm non-interventional study with asthma patients treated with Alvesco.
干预措施: Alvesco (Drug)
结局指标
主要结局
Treatment success with Alvesco
时间窗: after 3 months
Pre-/ post comparison of FEV1, Quality of life, Patient Questionnaire
次要结局
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability(after 3 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Efficacy of Ciclesonide During the Cold Season in Patients Older Than 12 Years With Persistent AsthmaAsthmaNCT00608218AstraZeneca2,100
已完成
3 期
A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 PatientsCOVID-19NCT04377711Covis Pharma S.à.r.l.400
已完成
4 期
Asthma Care With Alvesco® (Ciclesonide) in Primary Care in Adults - The ACCEPT-study (BY9010/CA-102)AsthmaNCT00404547AstraZeneca1,121
已完成
3 期
Asthma Clinical Research Network (ACRN) Trial - Long-Acting Beta Agonist Response by Genotype (LARGE)AsthmaNCT00200967Milton S. Hershey Medical Center87
已完成
2 期
Pilot Study in Patients With Symptomatic Steroid-Naive AsthmaAsthmaNCT00024544Facet Biotech120